



## SPECIAL FOCUS ON ONCOLOGY & HAEMATOLOGY SMC ADVICE

### Introduction

This Tayside Prescriber DTC supplement includes local recommendations for outstanding Oncology and Haematology SMC advice which has been agreed by the Oncology & Haematology Medicines Management Group (OHMMG). Links to relevant disease protocols (see below) have been added in the comments and useful links section.

### Oncology & Haematology Protocols

A programme of development of local Oncology and Haematology protocols was introduced in 2009-10. Approved protocols are now available through the Tayside Area Formulary (TAF).

From [the home page of TAF](#) click on **Specialist Formulary Lists and Formulary Development** link. This is from the index on the left hand side of the formulary, before the Palliative Care Guidelines and BNF sections and just above the Adverse Drug Reaction reporting link. From the list of specialist formularies, click on **Oncology & Haematology protocols** link. There are a few protocols that are still under development and will appear on the site once they have been finalised / approved by OHMMG.

### Updates from previous SMC Advice (Oncology/Haematology 2004 - 2011)

Medicine	Indication	Local recommendation category	Comments and useful links
Bortezomib 3.5mg vial of powder for solution for IV injection (Velcade®) (126/04) - Full submission	Treatment of patients with multiple myeloma who have received at least two prior therapies, have demonstrated disease progression on the last therapy and who are refractory to alternative licensed treatments for this stage of the disease.	Hospital only (Haematology)	<a href="#">SMC advice</a> <a href="#">Multiple Myeloma Protocol</a>
Bortezomib 3.5mg vial of powder for solution for IV injection (Velcade®) (302/06) - 2nd Re-submission	Mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.	Hospital only (Haematology)  Supplied via Patient Access Scheme (PAS)	<a href="#">SMC advice</a> <a href="#">Multiple Myeloma Protocol</a>
Carmustine 7.7mg implant (Gliadel®) (215/05) - Full submission	Treatment of newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation.	Hospital only (Neurosurgery)	<a href="#">SMC advice</a> <a href="#">Primary Glioma Protocol</a>

## Updates from previous SMC Advice (Oncology/Haematology 2004 - 2011) continued....

Medicine	Indication	Local recommendation category	Comments and useful links
Degarelix (Firmagon®) (560/09) - Re-submission	Gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer.	GPs may prescribe under the direction of the urology/ oncology clinic  Supplied via a Patient Access Scheme (PAS) (simple discount).  Restricted to hormone naïve metastatic prostate cancer patients with PSA>50 who have severe bone pain, spinal cord compression, or other serious complications of metastatic disease and who need rapid reduction of testosterone levels.	<a href="#">SMC advice</a> <a href="#">SPC link 80mg inj</a> <a href="#">SPC link 120mg inj</a>  Note that short-term treatment with anti-androgen is not required.  A general practice minor surgery fee is available for the administration of degarelix.
Docetaxel concentrate and solvent for solution for infusion (Taxotere®) (209/05) - Full submission	In combination with prednisolone for the treatment of patients with metastatic hormone refractory prostate cancer (mHRPC).	<b>Hospital only</b> (Oncology)	<a href="#">NICE MTA</a> <a href="#">Prostate Cancer Protocol</a>
Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion (Taxotere®) (201/05) - Full submission	In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of operable, node-positive breast cancer.	<b>Hospital only</b> (Oncology)	<a href="#">SMC advice</a> <a href="#">Breast Cancer Protocol</a>
Erlotinib 100mg and 150mg tablets (Tarceva®) (220/05) - Re-submission	Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.	<b>Hospital only</b> (Oncology)	<a href="#">SMC advice</a> <a href="#">Non-Small Cell Lung Cancer Protocol</a>
Exemestane 25mg tablets (Aromasin®) (210/05) - Full submission	Adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.	GPs may prescribe under the direction of the Oncology clinic	<a href="#">SMC advice</a> <a href="#">Breast Cancer Protocol</a>
Imatinib 100mg and 400mg film-coated tablets (Glivec®) (584/09) - Re-submission	Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117) - positive gastro-intestinal stromal tumours (GIST).	<b>Hospital only</b> (Oncology)	<a href="#">SMC advice</a> <a href="#">Upper GI Protocol</a>
Letrozole 2.5mg tablets (Femara®) (251/06) - Full submission	Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	GPs may prescribe under the direction of the Oncology clinic	<a href="#">SMC advice</a> <a href="#">Breast Cancer Protocol</a>
Nilotinib 200mg capsules (Tasigna®) (440/08) - Full submission	Treatment of chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib.	<b>Hospital only</b> (Haematology)	<a href="#">SMC advice</a> <a href="#">CML Protocol</a>
Pemetrexed 500mg infusion (Alimta®) (192/05) - Full submission	In combination with cisplatin is accepted for restricted use within NHS Scotland for the treatment of chemotherapy-naïve patients with stage III/IV unresectable malignant pleural mesothelioma.	<b>Hospital only</b> (Oncology)	<a href="#">SMC advice</a> <a href="#">Malignant Mesothelioma Protocol</a>

## Updates from previous SMC Advice (Oncology/Haematology 2004 - 2011) continued....

Medicine	Indication	Local recommendation category	Comments and useful links
Rituximab 100 & 500mg concentrate for solution for infusion (MabThera®) (540/09) - Full submission	First-line treatment of patients with chronic lymphocytic leukaemia (CLL) in combination with fludarabine and cyclophosphamide.	Hospital only (Haematology)	<a href="#">SMC advice</a> <a href="#">CLL Protocol</a>
Rituximab 100 & 500mg concentrate for solution for infusion (MabThera®) (591/09) - Full submission	Treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL) in combination with chemotherapy.	Hospital only (Haematology)	<a href="#">SMC advice</a> <a href="#">CLL Protocol</a>
Sunitinib 12.5mg, 25mg, 50mg hard capsule (Sutent®) (275/06) - Re-submission	Treatment of unresectable and / or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance.	Hospital only (Oncology)  Supplied via a Patient Access Scheme (PAS)	<a href="#">SMC advice</a> <a href="#">Upper GI Protocol</a>
Thalidomide 50mg hard capsule (Thalidomide Pharmion®) (525/08) - Full submission	In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged 65 years or over or ineligible for high dose chemotherapy,	Hospital only (Haematology)	<a href="#">SMC advice</a> <a href="#">Multiple Myeloma Protocol</a>
Topotecan 0.24mg, 1mg hard capsules (Hycamtina®) (545/0) - Full submission	Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.	Hospital only (Oncology)	<a href="#">SMC advice</a> <a href="#">Small cell lung cancer Protocol</a>

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Drug and Therapeutics Committee. Please direct any queries to either: Karen Harkness, Principal Pharmacist - Clinical Effectiveness, email: [kharkness@nhs.net](mailto:kharkness@nhs.net) or Claire James, Senior Pharmacist - Clinical Effectiveness, email: [clairejames@nhs.net](mailto:clairejames@nhs.net)